Anterior segment optical coherence tomography changes with introduction and discontinuation of tamsulosin

Abdullah Al-Kharashit,⇑; Amir A. Azimzadeh; Jerry Leung; Sidney Radomskic; Lenny Radomskic; Wai-Ching Lam

Abstract

Purpose: The aim of this study was to quantify changes and reversibility in pupil dilation and iris dilator muscle region thickness associated with introduction and subsequent discontinuation of tamsulosin in patients naïve to this drug with the aid of an anterior OCT system.

Methods: The study was carried out on 7 patients (14 eyes) naïve to tamsulosin and with benign prostatic hypotrophy (BHP). Measurements taken by Vistante OCT were done pre- and post-dilation of the following: pupil size, iris dilator muscle region (DMR) thickness, sphincter muscle region (SMR) thickness, and anterior chamber depth. These measurement were taken at Day 0 (tamsulosin naive), Day 30 (after one month of tamsulosin, the treatment period) and day 60 (after one month of no tamsulosin, the discontinuation period).

Results: Post-dilation pupil diameter significantly increased during the discontinuation period ($P = 0.047$). Iris DMR thickness measurements post-dilation significantly decreased during treatment ($P = 0.00044$), discontinuation ($0.00011$), and combined periods ($P = 0.000050$). Anterior chamber depth measurements in post-dilation were significantly decreased during treatment ($P = 0.0016$), discontinuation ($P = 0.017$), and combined periods ($P = 0.00022$).

Conclusion: Tamsulosin discontinuation effectively increases dilated pupil size, a measure that has been inversely linked to IFIS incidence pre-operatively. Decreased DMR thickness in this short term likely illustrates changes aside from atrophy, such as vascular changes. Decreased anterior chamber depths suggest aqueous humor production is decreased as well.

Keywords: Intraoperative floppy iris syndrome, Cataract surgery, Optical coherence tomography, Flomax, Tamsulosin, Benign prostatic hypertrophy

Introduction

Benign prostatic hyperplasia (BPH) is a common condition affecting 2.7% of men aged 45–49 years and as high as 24% for men over 80 years old.1 Pharmacological treatment of BPH involves the use of $\alpha_1$-adrenoreceptor antagonists, such as tamsulosin. This drug is now known to many ophthalmologists through its association with iris changes that complicate cataract surgery.2 These changes have been coined as intraoperative floppy iris syndrome (IFIS) by Chang and Campbell.3

References

1. Miller FG, Goldstein JL, O’Leary MD, et al. The American Urological Association’s guidelines for the management of benign prostatic hyperplasia. J Urol 2004;171:1905–1908. 2. Chang YT, Campbell G. The anti-impotence drug Flomax induces cataract surgery complications: a case report. J Cataract Refract Surg 2001;27:1083–1091. 3. Chang YT, Campbell G. Intraoperative floppy iris syndrome: a case report. J Cataract Refract Surg 2001;27:1726–1730.

© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

http://dx.doi.org/10.1016/j.sjopt.2016.07.005

Peer review under responsibility of Saudi Ophthalmological Society, King Saud University.
Anterior chamber OCT images of participants’ eyes were taken at 3 different points in time over a 2 month duration, prior to tamsulosin, at the end of 30 day tamsulosin course, and another 30 days after completion of therapy. Measurements were made by OCT Visante software (Carl Zeiss Co.) at each of the three points in time, before and after dilation of each eye with Diophenyl-T eyedrops (Phenylephrine Hydrochloride 5%; Tropicamide 0.8%).

Measurements of interest were as follows: pupil size, iris dilator muscle region (DMR) thickness, iris sphincter muscle region (SMR) thickness, and anterior chamber depth. These were measured from the OCT images through use of the anterior chamber OCT (Fig. 1).

All tests were performed in the same clinic with the same instruments during the course of the study. Patients were examined and evaluated for a complete eye history before starting the study including in clinic pretest slit lamp biomicroscopy examination for the evaluation of anterior chamber, pupils, diameter, and refractivity. Additionally, OCT imaging measurements of pupil size measured between papillary margins, iris dilator muscle region (DMR) measured halfway between the scleral spur and pupil margin and iris sphincter muscle region (SMR) measured within anterior 0.75 mm from pupil margin at the thickest and thinnest aspects were recorded. The anterior chamber depth (ASD) measured from the anterior border of lens to the posterior border of cornea was also recorded. None of the patients experienced any urinary symptoms or complications. There were no patients lost to follow-up during the study.

### Statistical analysis

Measurements for each eye at the start and end of the treatment, discontinuation, or combined period were analyzed using SPSS version 20.0 (IBM Inc., Chicago, Illinois, USA). Shapiro-Wilk test was used to test for normality and the data were not normally distributed; hence, Friedman test was used to compare the paired data. Each eye was treated as an independent sample. The null hypothesis was set as no difference between the start and end of a period for all measures of pupil diameter, iris thicknesses, and anterior chamber depth. Significance was considered as $P < 0.05$.

### Results

The post-dilation pupil diameter was found to be significantly increased during the discontinuation period.
Table 1. Pupil sizes expressed as mean ± standard deviation in mm.

| Stage of tamsulosin usage | Treatment period (Day–30) | Discontinuation period (Day–60) | Combined period (Day–60) |
|---------------------------|---------------------------|---------------------------------|--------------------------|
|                           | Day 0 (before tamsulosin exposure) | Day 30 (after 1 month of exposure) | Day 60 (after 1 month of discontinuation) | Difference between start and end | P-value | Difference between start and end | P-value | Difference between start and end | P-value |
| Pupil diameter change with dilation | 2.80 ± 0.70 | 2.81 ± 0.79 | 3.12 ± 0.62 | 0.02 ± 0.80 | 0.92 | 0.31 ± 0.87 | 0.24 | 0.32 ± 0.73 | 0.17 |
| Pre-dilation pupil diameter | 3.21 ± 0.64 | 2.96 ± 0.56 | 2.98 ± 0.46 | −0.25 ± 0.46 | 0.064 | 0.02 ± 0.56 | 0.92 | −0.23 ± 0.49 | 0.12 |
| Post-dilation pupil diameter | 5.93 ± 0.56 | 5.75 ± 0.81 | 6.07 ± 0.63 | −0.18 ± 0.59 | 0.33 | 0.32 ± 0.49 | 0.047 | 0.14 ± 0.39 | 0.26 |

Table 2. Dilator muscle region thicknesses expressed as mean ± standard deviation in mm.

| Stage of tamsulosin usage | Treatment period (Day 0–30) | Discontinuation period (Day 30–60) | Combined period (Day 0–60) |
|---------------------------|---------------------------|---------------------------------|--------------------------|
|                           | Day 0 (before tamsulosin exposure) | Day 30 (after 1 month of exposure) | Day 60 (after 1 month of discontinuation) | Difference between start and end | P-value | Difference between start and end | P-value | Difference between start and end | P-value |
| DMR pre-dilation thickness | 0.51 ± 0.053 | 0.48 ± 0.043 | 0.46 ± 0.041 | −0.030 ± 0.023 | 0.00032 | −0.019 ± 0.018 | 0.0015 | −0.049 ± 0.031 | 0.000051 |
| DMR post-dilation thickness | 0.63 ± 0.054 | 0.59 ± 0.061 | 0.57 ± 0.057 | −0.041 ± 0.032 | 0.00044 | −0.013 ± 0.0090 | 0.00011 | −0.054 ± 0.034 | 0.000050 |
### Table 3. Ratio value between dilator muscle region and sphincter muscle region expressed as mean ± standard deviation.

| Stage of tamsulosin usage | Treatment period (Day 0–30) | Discontinuation period (Day 30–60) | Combined period (Day 0–60) |
|---------------------------|-----------------------------|-----------------------------------|-----------------------------|
|                           | Difference between start and end | P-value  | Difference between start and end | P-value | Difference between start and end | P-value |
| Pre-dilation DMR/SMR ratio | 0.92 ± 0.18 | 0.88 ± 0.15 | 0.85 ± 0.13 | −0.047 ± 0.049 | 0.0028 | −0.029 ± 0.044 | 0.024 | −0.076 ± 0.066 | 0.00080 |
| Post-dilation DMR/SMR ratio | 1.1 ± 0.14 | 1.0 ± 0.13 | 1.0 ± 0.11 | −0.076 ± 0.066 | 0.0020 | −0.023 ± 0.022 | 0.0042 | −0.099 ± 0.073 | 0.00061 |

### Table 4. Thickest and thinnest sphincter muscle region thicknesses expressed as mean ± standard deviation in mm.

| Stage of tamsulosin usage | Treatment period (Day 0–30) | Discontinuation period (Day 30–60) | Combined period (Day 0–60) |
|---------------------------|-----------------------------|-----------------------------------|-----------------------------|
|                           | Difference Between Start and end | P-value  | Difference between start and end | P-value | Difference between start and end | P-value |
| Thickest pre-dilation SMR | 0.56 ± 0.10 | 0.56 ± 0.076 | 0.56 ± 0.077 | 0.0036 ± 0.040 | 0.71 | −0.00071 ± 0.0027 | 0.32 | 0.0029 ± 0.040 | 0.80 |
| Thickest post-dilation SMR | 0.58 ± 0.064 | 0.58 ± 0.068 | 0.58 ± 0.063 | −0.0025 ± 0.011 | 0.44 | −0.0017 ± 0.0083 | 0.48 | −0.0042 ± 0.012 | 0.21 |
| Thinnest pre-dilation SMR | 0.31 ± 0.029 | 0.31 ± 0.022 | 0.31 ± 0.023 | 0.00071 ± 0.011 | 0.83 | −0.00071 ± 0.0062 | 0.71 | 0.0 ± 0.013 | 0.998 |
| Thinnest post-dilation SMR | 0.31 ± 0.026 | 0.30 ± 0.024 | 0.31 ± 0.022 | −0.0058 ± 0.0090 | 0.047 | 0.0042 ± 0.0090 | 0.13 | −0.0017 ± 0.0072 | 0.43 |

Anterior segment OCT changes associated with tamsulosin
(+0.32 ± 0.49 mm, \( P = 0.047 \)). Other changes were not statistically significant. See Table 1 for the pupil diameter findings.

Iris DMR thicknesses at pre-dilation and post-dilation were significantly decreased during treatment, discontinuation, and combined periods. Changes in pre-dilation measurements during these periods, respectively, were \(-0.030 ± 0.023 \text{ mm} (P = 0.00032)\), \(-0.019 ± 0.018 \text{ mm} (P = 0.0015)\) and \(-0.049 ± 0.031 \text{ mm}, \( P = 0.000044 \)). Changes for post-dilation measurements during these periods, respectively, were \(-0.041 ± 0.032 \text{ mm} (P = 0.00044)\), \(-0.013 ± 0.0090 \text{ mm} (P = 0.00011)\), and \(-0.054 ± 0.034 \text{ mm} (P = 0.000050)\). See Table 2 for iris dilator muscle region thickness findings.

DMR/SMR ratios at pre-dilation and post-dilation were significantly decreased during treatment, discontinuation, and combined periods. Changes in pre-dilation measurements during these periods, respectively, were \(-0.047 ± 0.049 (P = 0.0028)\), \(-0.029 ± 0.044 (P = 0.024)\) and \(-0.076 ± 0.066 (P = 0.00080)\). Changes in post-dilation measurements during these periods, respectively, were \(-0.076 ± 0.066 (P = 0.0020)\), \(-0.023 ± 0.022 (P = 0.00042)\), and \(-0.099 ± 0.073 (P = 0.000061)\). See Table 3 for ratios of DMR to SMR for each eye.

There was no significant change in either thickest or thinnest SMR measurement at pre- or post-dilation during any period of the study. See Table 4 for SMR thickness values.

Post-dilation anterior chamber depth measurements were significantly decreased during treatment, discontinuation, and combined periods. Changes in post-dilation measurements during these periods, respectively, were \(-0.023 ± 0.019 (P = 0.0017)\), \(-0.026 ± 0.033 (P = 0.016)\), and \(-0.049 ± 0.032 (P = 0.00022)\). See Table 5 for anterior chamber depth values.

**Discussion**

The post-dilation pupil diameter was found to increase during the discontinuation period. This may be due to a decreased concentration of tamsulosin, which has a half-life of 14 h and is a competitive antagonist. In a study by Parssoninen, tamsulosin concentrations in aqueous humor were below quantification in one patient after a 21 day pause of therapy. Our findings suggest that pupil size changes secondary to tamsulosin may be reversible in the short-term.

A second contributing factor toward greater pupil diameter is upregulation of adrenergic receptors in response to drug exposure. This idea was proposed in a study with rats exposed to 1 month of tamsulosin treatment followed by 1 month of washout. It theorized the maintenance of upregulated \(\alpha_{1a}\)-AR washout in order to explain dilated pupil diameters of rats that were, albeit statistically insignificant, larger at washout than baseline when dilated with an alpha agonist but not with another mydriatic agent. The results in our study are similar. In an analysis by Panagis, an eye of significantly longer exposure did not show upregulation on immunoreactive histopathologic analysis.

Clinically, the possibility of reversibility of dilated pupil diameter with discontinuation of tamsulosin is important. Decreased diameters have been shown to have both an increase in severity and frequency of IFIS.

We found that DMR thickness decreased during treatment and, surprisingly, also during discontinuation of the
treatment. Decreased thickness during discontinuation period may be explained by the effect of the residual levels of the drug. Similar to this study, Prata found decreased DMR and DMR/SMR ratio values on OCT imaging of eyes exposed to tamsulosin for an average 28.2 months. Iris dilator muscle atrophy is also a plausible explanation to account for some of the thickness decreases in the Prata study.

Histologically, the muscular layer is a small portion of the iris thickness and its atrophy could not solely account for decreased thickness in this study. Nonetheless, atrophy within iris dilator muscle has been found in eyes exposed to longer durations of tamsulosin. Are there likely to be other components of the iris, such as the vasculature, which may account for the iris thickness changes in this study. Much of the iris structure is vascularized stroma composed of arterioles that do not bifurcate or anastamose. Immunohistochemical analysis by Panagis showed markedly decreased α1a-AR immunoreactivity of the arteriolar lumen of IFIS tissue compared to non-IFIS tissue. In contradiction to this, a study of rat iris arterioles showed a pharmacological response of these blood vessels consistent with the activation of α1b-AR, but not α1a-AR. However, this may be accounted for by difference between species. Vasculature changes may be dynamic as opposed to morphological as Panagis did not show iris morphological changes in IFIS eyes compared to control. A similar observation was found in a cadaveric study by Santaella that found no significant difference in iris stroma.

Despite lack of documented effect of an α1a-AR on iris arteriolar structure or function, Panagis proposed that iris vasculature provides the structural support for the iris and has the ability to coil and uncoil to allow for iris dilation. The loss of this arteriole coiling ability would decrease iris dilation. This would be consistent with our findings if this proposed coiling is structurally thinner. Vasoconstriction is also a possible explanation for iris thickness changes but α1-AR antagonism by prazosin has been observed to block vasoconstriction in rat iris arterioles. The effect of a selective α1a-AR antagonist such as tamsulosin on vascular function is not known. Furthermore, vascular dysfunction may also lead to iris dilator muscle atrophy due to a deterioration of arteriolar nutritive functions.

The findings of decreased anterior chamber depth by OCT were found only in dilated pupils. This may occur as a result of decreased aqueous humor. Alpha-1 ARs play a role in aqueous humor dynamics. Specific agonists for α1-ARs increase intraocular pressure while specific antagonists decrease intraocular pressure. A study by Zhan found that bunazosin (an α1-AR antagonist) treatment significantly decreased intraocular pressure with increased uveoscleral outflow in rabbits. A study by Krupin found prazosin (an α1-AR antagonist) decreased aqueous humor production but did not change outflow. In another study of prazosin, Chioi observed 55% reduction in aqueous humor production and 25% reduction in aqueous humor outflow during a 3 h period in the cat eye model. It would thus be expected that another α1-AR antagonist such as tamsulosin would also decrease aqueous humor volumes. A study by Suzuki found that the mRNA levels of different α1-AR subtypes in the ciliary body were 99.2% comprised of the α1-AR subtypes. The selectivity of tamsulosin for the α1A-AR subtype and its mRNA predominance in the ciliary body provides a physiological pathway for decreased aqueous humor as made evident in our study by decreased anterior chamber depth. Our study suggests that tamsulosin affects aqueous humor production and may provide benefit to glaucoma therapy. Tamsulosin’s effect on glaucoma has not been studied to our knowledge and provides an avenue for further research into its effects on anterior chamber depth, aqueous humor production and outflow, and intraocular pressure.

In conclusion, the findings of this study suggest pupil diameter changes are reversible and suggest possible reversibility of IFIS as well for short-term users. It demonstrates iris thickness effects but not the significance of this in relation to IFIS incidence remains to be determined. Our study demonstrates novel findings of an effect of tamsulosin on anterior chamber depth. This is likely through aqueous humor changes and is of relevance to glaucoma treatment. The findings of this study are limited by the small cohort size as well as a lack of placebo group to compare findings. Furthermore, the treatment period is short and conclusions cannot be extrapolated to long-term usage. Although the discontinuation follow-up period was thirty days, findings such as decreased DMR may normalize given longer follow-up. Directions for future research include anterior chamber depth, aqueous humor and intraocular pressure changes with tamsulosin in the context of glaucoma treatment effects. Furthermore, it remains to be determined whether or not discontinuing tamsulosin in short-term users has an effect on IFIS incidence and severity.

Conflict of interest

None.

Financial disclosure

No author has a financial or proprietary interest in any material or method mentioned in study.

References

1. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostate hyperplasia in primary care – the Triumph project. Eur. Urol. 2002;42:323–8.
2. Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology 2011;118:730–5.
3. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664–73.
4. Chen AA, Kelly JP, Bhandari A, Wu MC. Pharmacologic prophylaxis and risk factors for intraoperative floppy-iris syndrome in phacoemulsification performed by resident physicians. J Cataract Refract Surg 2010;36:898–905.
5. Theodossiadis PG, Achtsidis V, Theodoropoulou S, Tendentouris N, Kominos C, Fountas KN. The effect of alpha antagonists on pupil dynamics: implications for the diagnosis of intraoperative floppy iris syndrome. Am J Ophthalmol 2012;153:620–6.
6. Prata TS, Palmiero P, Angelilli A, Sbietz Z, De Moraes CGV, Liebmann JM, et al. Iris morphologic changes related to alpha1-adrenergic receptor antagonists. Implications for intraoperative floppy iris syndrome. Ophthalmology 2009;116:977–81.
7. Altan-Yacioglu R, Yacioglu O, Gul U, Pelit A, Adilbeli FM, Akova YA. The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized singleblind study. Naunyn Schmiedebergs Arch Pharmacol 2007;375:199–203.
8. Santaella RM, Destafeno JJ, Stinnett SS, Proia AD, Chang DF, Kim T. The effect of alpha1-adrenergic receptor antagonist tamsulosin (Flomax) on iris dilator smooth muscle anatomy. Ophthalmology 2010;117:1743–9.

9. Yaycioglu O, Altan-Yaycioglu R. Intraoperative floppy iris syndrome: facts for the urologist. Urology 2010;76:272–6.

10. Schwinn DA, Afshari NA. Alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophthalmol 2006;51:501–12.

11. Parssinen O, Leppanen E, Keski-Rahkonen P, Mauriala T, Dugue B, Lehtonen M. Influence of tamsulosin on the iris and its implications for cataract surgery. Invest Ophthalmol Vis Sci 2006;47:3766–71.

12. Altan-Yaycioglu R, Yaycioglu O, Tufan H, Akova YA, Ozkardes H. The effects of systemic alpha-1 adrenergic antagonists on pupil diameter in rats. Curr Eye Res 2007;32:217–21.

13. Panagis L, Basile M, Friedman AH, Danias J. Intraoperative floppy iris syndrome: report of a case and histopathologic analysis. Arch Ophthalmol 2010;128:1437–41.

14. Casuccio A, Cillino G, Pavone C, Spitale E, Cillino S. Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome. J Cataract Refract Surg 2011;37:1447–54.

15. Friedman AH. Tamsulosin and the intraoperative floppy iris syndrome. JAMA 2009;301:2044–5.

16. Gould DJ, Hill CE. Alpha 1B-receptors and intracellular calcium mediate sympathetic nerve induced constriction of rat irideal blood vessels. J Auton Nerv Syst 1994;50:139–50.

17. Suzuki F, Taniguchi T, Nakamura S, Akagi Y, Kubota C, Satoh M, et al. Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes. Br J Pharmacol 2002;135:600–8.

18. Zhan GL, Toris CB, Camras CB, Wang YL, Yablonski ME. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. J Ocul Pharmacol Ther 1998;14:217–28.

19. Krupin T, Feitl M, Becker B. Effect of prazosin on aqueous humor dynamics in rabbits. Arch Ophthalmol 1980;98:1639–42.

20. Chiou GC. Effects of alpha 1 and alpha 2 activation of adrenergic receptors on aqueous humor dynamics. Life Sci 1983;32:1699–704.